Takeda, Endo Face Another Reverse-Payment Suit Over Drug Amitiza

Aug. 3, 2021, 8:01 PM

The operator of Kinney Drugs retail chain sued Takeda Pharmaceutical Co. and Endo International Plc over claims that the pharmaceutical manufacturers allegedly engaged in a pay-to-delay scheme to keep generic versions of Takeda’s anti-constipation drug Amitiza off the market.

KPH Healthcare Services Inc.'s antitrust lawsuit, filed Tuesday in the U.S. District Court for the District of Massachusetts, said that Japan-based Takeda and its U.S. subsidiary, Takeda Pharmaceuticals USA Inc., made “reverse payments” totaling between $29 and $280 million to an Endo subsidiary, Par Pharmaceuticals, to keep the generic from being introduced for over six years.

It’s the second lawsuit Takeda ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.